Originally published by Gilead Sciences

By Daniel O’Day

As the disturbing events in Ukraine continue to unfold, Gilead’s initial priority has been to safeguard our employees in the region. At the same time, our teams have been working with urgency to mitigate any impact on the supply of our medicines to patients who depend on them.

We are all alarmed by the far-reaching impact on innocent people in the region and like many of us watching from afar, we feel driven to do what we can to help. One immediate action we can take is to donate resources. The Gilead Foundation will donate USD 3 million to support humanitarian efforts in Ukraine, with funds going to three organizations: USA for UNHCR (UN Refugee Agency), UNICEF USA and International Medical Corps (IMC).This donation is in addition to the more than USD 300 thousand already raised by Gilead employees, as part of our employee donation matching campaign for Ukraine.

We also continue to reach out to Gilead’s long-standing grantee organizations in both Ukraine and Russia who rely on our support to reach vulnerable communities, particularly people living with HIV. We will stay in close contact with these organizations to determine what additional resources or help they might need as things evolve.

At times like this, we feel that organizations that are in a position to help have a responsibility to do so in whatever ways are possible. The people of Ukraine are in our thoughts and our hearts as we hope for a swift resolution to the crisis.

Originally published by Gilead Science

Gilead Sciences

Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

More from Gilead Sciences